All News

Physician employment contracts with hospitals that were signed in the early days of healthcare reform are coming up for renewal Experts say the expectation of payment reform requires that these new deals include the flexibility to adapt to expected and unforseeable changes.

Cobimetinib (MEK inhibitor), used in combination with Zelboraf (BRAF inhibitor), improved survival without disease progression.

In vitro studies demonstrated a reduced incidence of apoptosis in patients administered inhaled anesthetics compared with those administered propofol during surgery.

High expression of PD-L1 was associated with the presence of EGFR mutations in surgically resected NSCLC and was an independent negative prognostic factor for this disease.

Most providers associate clinical documentation improvement (CDI) with the transition to ICD-10 coding, however, CDI - a process in which care providers receive feedback from specialists who review clinical documents - may also deliver clinical and financial benefits for healthcare organizations.

Fewer patients linger for days in hospitals without being admitted because of a new federal rule, but hospital and consumer groups are suing the government because they say the policy compromises Medicare patients' care, and patients are often stuck with costly, unexpected bills.

It's easy to get swept up in the swelling enthusiasm for using the explosion in electronic health and claims records to improve every aspect of healthcare. But the era of "big data" isn't going to happen without better federal rules for stimulating its uses and preventing abuses.

Primary care doctors surveyed by the Medical Group Management Association say nearly 6% of their compensation was pegged to quality metrics in 2013, up from 3% in 2012.

One insurer's experimental reimbursement model proved to lower the total costs of care for patients with 3 types of cancer. As an alternative to the traditional fee-for-service payment model, the episode payment model-which reimburses physicians on a fixed-price, based on episodes of best-practices and patient outcomes-provided encouraging findings in the battle against the rising costs of cancer care in the United States.

House Republicans took the initial step on Thursday to sue President Barack Obama over the administration's decision to delay the employer mandate of the healthcare law.

Collaborative research conducted by scientists within the Cancer Genome Atlas Research Network have identified significant mutations that can influence tumor subtype classification.

While much attention has focused on expanded coverage and online insurance bazaars, policymakers' bigger challenge is improving Americans' health while putting a brake on the cost of their care. The keys to that puzzle, CareFirst and many others are deciding, are the internists and general practitioners who have largely been left behind by health care's financial boom.

Following approval in Japan, Nivolumab will be evaluated by the FDA for melanoma therapy in the US.

Dr. Howard Koh is stepping down as assistant secretary for health at HHS after five years in the post. Koh's primary focus was disease prevention, including oversight of the Office of the Surgeon General.

There has been a sharp increase in the number of cancer patients at one hospital using MyChart, the online, interactive service that allows patients to view laboratory and radiology results, communicate with their healthcare providers, and more.

The patient-centered medical home (PCMH) has been described as a model of "whole person" care delivery, 1 that is designed to support the goals of the Triple Aim. With team collaboration, the PCMH enhances patient access as well as their continuity of care. Now, 1 insurer reports that 1.1 million people who received care through its PCMH in 2013 were not only hospitalized less often, but they reported shorter lengths of stay than patients in fee-for-service care.

In one of the largest tests of a novel way to deliver and pay for healthcare, insurer CareFirst BlueCross BlueShield announced on Thursday that 1.1 million people receiving care through its "patient-centered medical homes" last year were hospitalized less often and stayed for fewer days compared to patients in traditional fee-for-service care.

UnitedHealthcare published these findings in the latest issue of Journal of Oncology Practice.

Federal agencies remain committed to increase patients' access to affordable, high quality, and comprehensive healthcare.

The study by researchers at MD Anderson Cancer Center raises the possibility of using the information provided by these dysfunctional genes.

The leaders of ACOs are working their way through a welter of immediate and longer-term issues.

With spending on diagnostics alone for cardiovascular disease likely to be a major challenge for insurers amid the baby boom wave, Aetna is turning to an emerging option as part of a strategy to avoid invasive tests and treatments.

Several cancer centers have programs in place to improve communication between PCPs and oncologists.

HHS Secretary Sylvia Mathews Burwell announced today the availability of $100 million from the Affordable Care Act to support an estimated 150 new health center sites across the country in 2015.

The Affordable Care Act (ACA) prohibits insurance companies from rejecting new customers based on their pre-existing health conditions. Yet, a recent report alleged that 4 Florida-based payers may have structured their prescription drug benefit plans in a way which does just that.

A lipid metabolite, associated with more than 70 percent of brain cancers, can help distinguish and excise cancerous tissue.

Wellness and behavioral health visits are among a few telehealth coverage expansions the CMS wants to add to the list of Medicare-reimbursable telehealth activities under a proposal released Thursday.

Over the past few decades, 38 states and the District of Columbia have switched their Medicaid plans to some form of managed care for at least part of their government programs.

Nivolumab, the first PD-1 inhibitor, was approved in Japan for treating unresectable melanoma. It has been developed in Japan by Ono Pharmaceutical, which also has rights in Korea and Taiwan.

GSK has received marketing authorization from the European Commission for trametinib as monotherapy for unresectable or metastatic melanoma in adults with a BRAF V600 mutation.